Losartan
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 422.91 |
| Cas No. | 114798-26-4 |
| Formula | C22H23ClN6O |
| Solubility | ≥2.48 mg/mL in H2O with gentle warming and ultrasonic; ≥2.9 mg/mL in EtOH with gentle warming; ≥84.6 mg/mL in DMSO |
| Chemical Name | [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol |
| SDF | Download SDF |
| Canonical SMILES | CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Cell experiment:[1] | |
|
Cell lines |
Vascular smooth muscle cells (VSMCs) |
|
Reaction Conditions |
0, 1, 5, 10 μM losartan for 48 h incubation |
|
Applications |
Losartan dose-dependently decreased the angiotensin Ⅱ (Ang Ⅱ)- or 15% fetal bovine serum (FBS)-induced VSMC proliferation by inhibiting the expression of cell cycle associated proteins, such as p-Rb, cyclin D, and cyclin E. |
| Animal experiment:[2] | |
|
Animal models |
Wistar-Kyoto (WKY) rats and stroke-prone, spontaneously hypertensive rats (SHR-SP) |
|
Dosage form |
10 mg/kg/day Administered by oral route for 2 weeks |
|
Applications |
In SHR-SP, losartan decreased systolic blood pressure, increased the number of circulating endothelial progenitor cells (EPCs) and colony formation, and inhibited oxidation. In addition, losartan was able to stimulated EPC migration. These data suggest that losartan can improve the proliferation and function of EPCs in hypertension, with the potential to repair hypertensive vascular injuries. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Kim JE, Choi HC. Losartan inhibits vascular smooth muscle cell proliferation through activation of AMP-activated protein kinase. The Korean Journal of Physiology & Pharmacology, 2010, 14(5): 299-304. 2. Yao EH, Fukuda N, Matsumoto T, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertension Research, 2007, 30(11): 1119-1128. |
|
质量控制和MSDS
- 批次:
化学结构
